Business Wire

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer

Jaa

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in The Lancet Oncology.

Based on the results, Servier filed a new application for an additional indication for gastric cancer to the European Medicines Agency (EMA) for LONSURF®.

“Patients with metastatic gastric cancer currently have limited treatment options after first and second line therapies have failed,” said Dr. Arkenau. “We are pleased to present new data that demonstrate the overall survival clinical benefit of trifluridine/tipiracil in metastatic gastric and gastroesophageal cancer.”

In TAGS patients treated with trifluridine/tipiracil showed a clinically meaningful and statistically significant improvement in OS compared with placebo and a 31 percent risk reduction of death (HR 0.69 one sided p=0.00029), which translated into a prolonged median survival of 2.1 months (5.7 months for trifluridine/tipiracil versus 3.6 months for placebo). In addition, trifluridine/tipiracil demonstrated a statistically significant improvement in PFS and time to deterioration of ECOG performance status versus placebo, as well as a predictable and manageable safety profile consistent with that previously reported in patients with metastatic colorectal cancer.

“We’re very excited by the results of TAGS as they show trifluridine/tipiracil has the potential to make a difference to the lives of people living with metastatic gastric cancer who continue to struggle with this devastating disease,” said Patrick Therasse, Head of Servier Research and Development Oncology Department.

Trifluridine/tipiracil is currently indicated in 61 countries, including those of the European Union, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1

The abstract for the trifluridine/tipiracil presentation is available on the ESMO website and the manuscript is published online in The Lancet Oncology.

ENDS

About TAGS
TAGS ( TA S-102 G astric S tudy) is a Taiho-sponsored pivotal Phase III, multinational, randomized, double-blind study evaluating trifluridine/tipiracil, also known as TAS-102, plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer, including gastro esophageal junction cancer, refractory to standard treatments. The primary endpoint in the TAGS trial is overall survival (OS), and the main secondary endpoint measures include progression-free survival (PFS), and safety and tolerability, as well as quality of life.

TAGS enrolled 507 adult patients with metastatic gastric cancer who had previously received at least two prior regimens for advanced disease. The study was conducted in Japan, the United States, the European Union, Russia, Belarus, Israel, and Turkey.

For more information on TAGS, please visit www.ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT02500043). The ClinicalTrials.gov Identifier is NCT02500043.

About Metastatic Gastric Cancer
Gastric cancer, also known as stomach cancer, is a disease in which malignant cells form in the lining of the stomach. It is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimated 723,000 deaths annually.2 

When cancer spreads it is called advanced cancer. Locally advanced cancer is when the cancer has grown outside the organ it started in but hasn’t spread to other parts of the body. When the cancer spreads to other parts of the body this is called metastatic cancer. In the last two decades, the proportion of patients with gastric cancer who present with metastases has risen to over 40%.3

Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes (with ramucirumab), or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third-line treatments are limited.

About LONSURF ® (trifluridine and tipiracil, TAS-102)
LONSURF ® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF ® is registered in Japan, USA, European Union, and in many other countries. In the European Union, LONSURF ® is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1

LONSURF ® is recommended by the National Institute for Health and Care Excellence (NICE),4 NCCN5,6 and ESMO Guidelines7 for the treatment of adult patients with metastatic CRC.

In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of LONSURF ® .

As of October 2018, LONSURF ® has been approved as a treatment for mCRC in 61 countries and regions worldwide.

About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as various leukemias and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, and targeted therapies, to deliver life-changing medicines to patients.

For more information about Servier, please visit www.servier.com .

About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/.

ENDS

1 EMA. Summary of product characteristics: LONSURF. Available at: https://www.ema.europa.eu/documents/product-information/lonsurf-epar-product-information_en.pdf Accessed October 2018.

2 Ferlay J, Soerjomataram I, Dikshit R, et al. Int J Cancer. 2015;136:E359-86.

3 Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–60.

4 NICE TA405. Available at: www.nice.org.uk/guidance/TA405 Accessed October 2018.

5 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

6 National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.

7 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.

Contact information

Servier
Sonia MARQUES
media@servier.com
Tél. +33-(0)1-55-72-40-21 / + 33-(0)-7-84-28-76-13
or
Karine BOUSSEAU
media@servier.com
Tél. +33-(0)1-55-72-60-37

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Manifesto: Call for a Successful Transition to Renewables in the Transportation Sector21.11.2018 16:04Tiedote

Political course corrections, coupled with the alarming reports on climate conservation, have led the organizers behind Power2Drive and other endorsers to initiate a manifesto. The aim is to deepen the close connection between e-mobility and renewable sources of energy and achieve a sustainable future. The smarter E Europe, the largest energy industry platform in Europe, will demonstrate the potential held by this combination of mobility and clean energy, and the pressing need to pay greater attention to sector coupling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005307/en/ Survey shows: Solar power for refuelling is popular (© Solar Promotion GmbH & Bundesverband Solarwirtschaft e.V. BSW) The organizers behind Power2Drive have formed a strong alliance committed to the idea of a successful transition to renewable sources of energy in the transportation sector. Some of the declaration’s first signatories include the

Knopp Biosciences to Present at the Piper Jaffray 30th Annual Healthcare Conference21.11.2018 14:00Tiedote

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference to be held in New York, NY on November 27-29. Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, November 27th at 12:50 p.m. Eastern Time. ABOUT KNOPP BIOSCIENCES LLC Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, ti

REPLY: Syskoplan Reply Awarded with the SAP Quality Award in the Innovation Category21.11.2018 12:00Tiedote

Syskoplan Reply, the SAP technology specialist within the Reply Group, has been awarded with the SAP Quality Award from SAP in the Innovation category for a project for the SEA Group. The award honors the latest SAP solutions and it is presented annually at the SAP NOW event. Syskoplan Reply receives the renowned award for the fifth time in a row. The gold award winning project is an innovative SAP Hybris Marketing solution for SEA from Syskoplan Reply. The SEA Group manages both Milan Linate and Milan Malpensa airports and provides all services and related activities. The project consists of implementing SAP Hybris Marketing to design, create and monitor marketing initiatives. The aim is to increase the customer experience of passengers at Milan Malpensa Airport and make their stay a special experience. The cross-departmental, effective marketing campaign is based on the concept of gamification: in the multi-channel campaign, passengers can participate in a treasure hunt "Hashtag Hunt

GSMA Launches New Industry-Wide Initiative to Support Development of Operator Edge Cloud AR/VR21.11.2018 12:00Tiedote

The GSMA today announced the launch of a new industry-wide initiative called The GSMA Cloud AR/VR Forum that will focus on the development of cloud virtual reality (VR) and augmented reality (AR) technology. The programme which was unveiled at Huawei’s 9th Global Mobile Broadband Forum in London, is backed by mobile operators including China Mobile, China Telecom, China Unicom, Deutsche Telekom, KDDI, KT Corp., NTT DOCOMO, SK Telecom, Telefónica, Telenor, TIM, Turkcell and Vodafone, as well as other industry partners including Huawei and HTC. The programme aims to encourage all parties to collaborate on accelerating the delivery and deployment of 5G cloud-based AR/VR services. “Both VR and AR are disruptive forms of immersive multimedia that, combined with operator edge cloud and 5G connectivity, will transform the cost structures of the enterprise and entertainment fields,” commented Alex Sinclair, Chief Technology Officer, GSMA. “Mobile operators will play a key role in its developme

Clientron to exhibit its embedded computing innovations at SPS IPC Drives 201821.11.2018 12:00Tiedote

Clientron Corp., a world-leading supplier of embedded systems, will introduce its intelligent embedded solutions including single board computers, embedded box PC, and industrial panel PC at SPS IPC Drives 2018, taking place at the Exhibition Centre Nuremberg (No.8-512, Hall 8) from 27 to 29 November in Nuremberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005002/en/ Clientron to exhibit its brand new intelligent embedded systems at SPS IPC Drives 2018 (Photo: Business Wire) The SPS IPC Drives is the leading trade fair for electronic automation solutions. At the show, Clientron will proud to illustrate its embedded computing solutions for factory automation and food industry applications. The advantages of Clientron’s products are designed for high quality, durability, flexibility and maximum compatibility to facilitate the business transformation towards Industry 4.0. During the show, Clientron will intro

Wireless charging makes a world’s first debut on South Western Railway trains in the UK.21.11.2018 12:00Tiedote

Baker Bellfield, one of the UK’s leading suppliers of commercial interior solutions for the rail sector, and Aircharge, global leader in wireless charging solutions for contract use, have announced today the launch of the world’s first fully rail compliant inductive phone wireless charging system. On-train wireless charging will debut on South Western Railway’s (SWR) refurbished and reconfigured class 444 Siemens Desiro five-car EMUs on the London Waterloo – Southampton – Bournmouth – Weymouth route from November 2018. When the refurbishment programme is completed, all 172 of SWR Desiro class trains will have this new feature. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005180/en/ The Aircharge - Baker Bellfield mobile phone wireless charging solution for trains (Photo: Business Wire) With mobile devices becoming the best travel companions for personal and business purposes, including the use of mobile check-in appl

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme